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Introduction
Inﬂ ammation initiated by an immune response targets 
epithelial cells, leading to cytotoxic eﬀ ects, and is a key 
driver of several disease conditions in the gastrointestinal 
(GI) tract [1]. Chronic inﬂ ammation leads to increased 
oxidative stress and long-term consequences, most 
notably cancer [2]. Oxidative stress is caused, in part, by 
highly reactive oxygen species (ROS) and nitrogen species 
(for example, superoxide anions, hydrogen peroxide, 
nitric oxide, and peroxynitrite), which can damage pro-
teins, lipids, DNA, and organelles, leading to altered 
pheno typic patterns, the induction of metaplasia, the 
transformation of the epithelium, and the emergence of 
cancer [2,3].
Inﬂ ammation-associated conditions in the GI tract 
include gastroesophageal reﬂ ux disease (GERD), Barrett’s 
esophagus (BE), graft-versus-host disease (GVHD), and 
inﬂ ammatory bowel disease (IBD; that is, ulcerative 
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colitis and Crohn’s disease). Induction of GERD and BE 
requires gastric acid and bile reﬂ ux to induce tissue 
injury, which results in the release of proinﬂ ammatory 
cytokines and subsequent recruitment of inﬂ ammatory 
cells [4-6], while GVHD results from donor-derived 
T lymphocytes damaging host tissue in response to MHC 
disparities [7], and ulcerative colitis and Crohn’s disease 
are caused, in part, by dysregulation of mucosal immunity 
[8]. Th ese diseases are important US healthcare concerns 
associated with signiﬁ cant morbidity and mortality 
[9-12].
Knowledge gaps
Mouse transgenic and surgical models have been the 
primary means of mechanistic studies for investigating 
inﬂ ammation-based GI diseases. While these models 
have been useful, they have obvious limitations because 
mice do not normally develop BE or ulcerative colitis 
[13]. Improved models based on human cells and tissues 
are urgently needed to understand pathogenesis as well 
as to explore novel therapeutic strategies. Th e lack of 
robust models has been a major impediment to these 
ﬁ elds.
Cell culture has been used in several forms for the 
study of GI disease [14]. Th e use of human cells in tissue 
culture systems, such as proposed here, allows for the 
ability to mimic the in vivo interplay between the epi-
thelium, immune cells, and the underlying stroma, 
providing a microphysiologically relevant environment 
[14] (Figure  1a). Immune cells activated in response to 
tissue injury or other mechanisms are signiﬁ cant 
producers of ROS, including hydrogen peroxide, and 
secrete cytokines that further amplify endogenous and 
exogenous ROS (Figure 1b,c). In the esophagus and intes-
tine, esophagitis and acute IBD elicit the expression of T-
helper type 1 proinﬂ ammatory cytokines such as IL-1β, 
IL-8, and IFNγ, while BE and the later stages of IBD 
present with a predominantly T-helper type  2 humoral 
response, with signiﬁ cantly increased levels of IL-4 
[15,16]. However, the mechanism by which this inﬂ am-
matory process results in metaplasia, dysplasia, and 
cancer is not known.
Current models suggest ROS generated by immune cell 
responses induce DNA single and double-stranded breaks 
or modify DNA bases by forming adducts (Figure  1a). 
Th e major forms of oxidative DNA damage are nonbulky 
lesions such as 8-oxo-2’-deoxyguanosine and thymine 
glycol [17]. Th ese modiﬁ cations can lead to base mis-
pairing and point mutations that, if not corrected prior to 
DNA replication, can cause mutations that activate 
oncogenes or inactivate tumor suppressors [18]. 
Furthermore, epigenetic changes in gene expression can 
also enhance disease progression [19]. Using artiﬁ cial 
approaches (addition of hydrogen peroxide to cell 
cultures), oxidative stress was recently established to 
profoundly alter epigenetic patterning in vitro [17]. Using 
physiologically rele vant conditions, however, it remains 
unproven whether the oxidative stress associated with 
inﬂ ammatory responses is the primary driver of the 
pathogenesis of BE, GVHD, and IBD, and the dysplasia 
and cancer associated with BE and IBD.
Esophageal three-dimensional (3D) organotypic culture 
(OTC) methods utilize epithelial cells grown on top of 
collagen/Matrigel matrices containing human fetal eso-
phageal ﬁ broblasts [20]. OTC methods provide a highly 
physiological relevant model for studying esopha geal 
squamous epithelial growth and diﬀ erentiation. However, 
the full potential of this culture system to model human 
disease conditions such as BE has not been fully explored. 
Fibroblasts are an essential compo nent of the 3D OTC 
system; they remodel the matrix and secrete factors that 
support squamous epithelial cell proliferation and 
diﬀ erentiation [20]. BE epithelial cells probably require 
diﬀ erent factors to sustain their growth. Several studies 
have identiﬁ ed some of these factors; in vivo they include 
bone morphogenetic protein  4 and wingless int-1 
protein-2 [21,22], and in vitro they include Noggin, wing-
less int-1 protein-3a, and R-spondin-1 [23]. In addition, 
the activity of the oncogene cyclooxygenase-2 is induced 
in ﬁ broblasts as well as in the epithelium in GERD and 
BE [24]. Our laboratory previously demon strated that 
endogenous overexpression of cyclooxy genase-2 in 
epithelial cells in 3D OTC results in the development of 
intestinal mucin-ﬁ lled epithelial cysts, consistent with 
the progression of BE development [25]. Nevertheless, 
the extent that factors produced from ﬁ broblasts 
inﬂ uence BE disease development and/or progression is 
largely unknown.
In 2011, four groups independently published descrip-
tions of methods by which human intestinal and colonic 
stem cells can be maintained and expanded in culture to 
mimic in vivo microenvironments [23,26-28] (Figure 2a). 
Th ese techniques built upon and extended a slightly 
older, more established method of culturing mouse small 
intestine stem cells [29]. In this culture method, human 
intestinal and colonic crypts or puriﬁ ed stem cells are 
embedded in Matrigel. Over several days these cells form 
spherical or elongated oval structures with a crypt-like 
lumen, referred to as human enterospheres [30] 
(Figure 2b). Small intestine and colon spheres can expand 
into multilobulated enteroids (Figure  2c) and colonoids 
that mimic the ordered structure of the epithelium 
complete with crypts containing multipotent columnar 
base stem cells and Paneth cells. Th e remaining cell types, 
including enterocytes, goblet cells, and enteroendocrine 
cells [23,30], can be observed in larger cysts away from 
the stem cell compartment (Figure  2a). While the 
majority of studies conducted with human enteroids and 
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colonoids thus far have focused on stem cell charac ter-
ization and regenerative medicine, there is immense 
potential for this culture system in GI research, 
particularly to model GVHD and IBD. However, they 
have not as yet been widely adopted to model these and 
other human disease conditions.
Future needs and research directions
Our work seeks to develop novel multicellular in vitro 
human tissue engineered models that physiologically 
recapitulate the acute and chronic inﬂ ammatory micro-
environment in order to model the eﬀ ects of oxidative 
injury on the epithelial cells of the esophagus and intestine. 
Th ese studies are anticipated to yield well-charac terized 
culture systems that are representative of the pathogenesis 
of GERD, BE, GVHD, and IBD, thereby providing useful 
laboratory models for these conditions. Experimental 
models for these conditions utilizing human tissues and 
cells are an unmet research imperative.
In addition, we anticipate more speciﬁ c products of our 
eﬀ orts. Th e development of a dynamic multicellular 
system to physiologically model inﬂ ammation will permit 
a more mechanistic understanding of the contributions 
of inﬁ ltrating immune cells and oxidative stress to DNA 
damage and epigenetic changes, particularly regarding 
their contribution to the progression to dysplasia and 
cancer. Moreover, these novel human cell tissue models 
can place human mucosal immunology research back in 
its appropriate context; that is, human epithelial systems. 
Pursuit of this end will require modiﬁ cations of our 
currently established 3D organotypic and intestinal 
enteroid/colonoid culture systems to reﬂ ect the 
inﬂ ammatory processes active during human diseases 
such as GERD, BE, GVHD, and IBD. Lastly, these human 
cell-based models of chronic inﬂ ammatory conditions 
can serve as a platform for testing novel therapeutic 
drugs and chemopreventive agents.
We are presently pursuing several important research 
directions. Th e ﬁ rst is to better characterize the contri-
butions of ﬁ broblasts to the growth and diﬀ erentiation of 
the squamous epithelium in the OTC system. Speciﬁ cally, 
we are exploring whether ﬁ broblasts function primarily 
to remodel the underlying matrix by altering physical 
properties such as stiﬀ ness, or instead secrete required 
growth and maintenance factors, or some combination of 
both. Moreover, we are investigating whether we can 
engineer the ﬁ broblasts to secrete other growth factors 
that support columnar epithelial growth, to determine 
whether this can promote epithelial metaplasia as 
observed in BE.
Figure 1. Modeling infl ammation in the esophagus. (a) Diagram illustrating how activated immune cells produce signifi cant amounts of 
reactive oxygen species (ROS), resulting in increased oxidative stress and DNA damage, which in turn disrupts the integrity of the epithelium, 
leading to apoptosis, and contributing to the evolution of diseases including Barrett’s esophagus (BE) and cancer. (b), (c) Histological analysis of 
esophageal keratinocytes grown under organotypic conditions in the presence of active immune cells.
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We are actively exploring modiﬁ cations to both the 
esophageal OTC and intestinal enteroid/organoid culture 
systems that will permit the inclusion of viable puriﬁ ed 
human immune cells (Figures  1b,c and 2b). We plan to 
further reﬁ ne the human OTC and intestinal enteroid/
colonoid cultures to include additional microenviron-
mental cell types and factors to better and more 
physiologically model human disease. For instance, 
eliciting a polarized response of puriﬁ ed human immune 
cells against the mismatched human leukocyte antigen of 
the growing human enteroid would provide an excellent 
model for GVHD. Once optimized, these co-culture 
systems could evaluate the eﬃ  cacies of novel immuno-
suppressant drugs and strategies to treat GVHD.
Conclusion
Our research eﬀ orts are focused on developing physio-
logically relevant human cell-based tissue culture models 
for chronic inﬂ ammatory conditions of the GI tract. With 
these systems we will mechanistically explore the eﬀ ect 
of the inﬂ ammatory response on epithelial oxidative 
stress and DNA damage. Ultimately, these novel model 
systems have the potential to permit the rapid testing of 
hypotheses and advance our understanding of chronic 
Figure 2. Modeling infl ammation in the intestine. (a) Diagram depicting the structure of an intestinal crypt in vivo, as well as the resulting in vitro 
organoid. The impact of oxidative stress and DNA damage resulting from reactive oxygen species (ROS)-producing immune cells is also shown. 
CBC, columnar base stem cells. (b) Human organoid co-cultured with dsRed-labeled mouse splenocytes (400×). (c) Human intestinal organoid 
9 days post isolation (100×).
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inﬂ ammatory disorders. Moreover, this research will 
foster the development of novel therapeutic and 
preventive strategies that will improve the lives and well-
being of patients aﬄ  icted with these important clinical 
conditions.
Abbreviations
BE, Barrett’s esophagus; 3D, three-dimensional; GERD, gastroesophageal refl ux 
disease; GI, gastrointestinal; GVHD, graft-versus-host disease; IBD, infl ammatory 
bowel disease; IFN, interferon; IL, interleukin; OTC, organotypic culture; ROS, 
reactive oxygen species.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KGH was responsible for drafting the manuscript and diagram design. JDB 
was responsible for drafting the manuscript and for image acquisition. GWF, 
JY, MGM, and AKR were responsible for the concept and critical manuscript 
revision. JPL was responsible for the concept and experimental design, critical 
manuscript revision and fi nal approval. All authors read and approved the fi nal 
manuscript.
Acknowledgements
The authors would like to thank the University of Pennsylvania Morphology 
and Pathology Imaging Core facility for their technical expertise and 
assistance. Tissue samples were kindly provided by the Cooperative Human 
Tissue Network, which is funded by the National Cancer Institute. This work is 
supported as part of the Integrated Microphysiological Systems program and 
the Intestinal Stem Cell Consortium with funding to JPL (TR 000536 and DK 
085551) and to MGM (DK 085535). This work was also supported by an NCI 
Program Project PO1 CA098101 (to AKR) and by the Morphology, Cell Culture, 
and Molecular Biology Core Facilities of the Center for Molecular Studies in 
Digestive and Liver Disease at the University of Pennsylvania (P30-DK050306 
and PO1 CA098101 to AKR). Publication costs were paid by the Integrated 
Microphysiological Systems program with funding to JPL (TR 000536).
Declarations
Publication of this supplement has not been supported by sponsorship. 
Articles have undergone the journal’s standard review process. The Editors 
declare that they have no competing interests.
This article has been published as part of Stem Cell Research & Therapy 
Volume 4 Supplement 1, 2013: Stem cells on bioengineered 
microphysiological platforms for disease modeling and drug testing. 
The full contents of the supplement are available online at 
http://www.stemcellres.com/supplements/4/S1.
Author details
1Division of Gastroenterology, Department of Medicine, Abramson Cancer 
Center, University of Pennsylvania, 3451 Walnut Street, Philadelphia, PA 19104, 
USA. 2Department of Pathology, University of Pittsburgh Cancer Institute, 
University of Pittsburgh School of Medicine, 5117 Centre Avenue, Hillman 
Cancer Center Research Pavilion, Pittsburgh, PA 15213, USA. 3Department of 
Radiation Oncology, University of Pittsburgh Cancer Institute, University of 
Pittsburgh School of Medicine, 5117 Centre Avenue, Hillman Cancer Center 
Research Pavilion, Pittsburgh, PA 15213, USA. 4Department of Pediatrics, 
Division of Gastroenterology and Nutrition, Mattel Children’s Hospital and 
the David Geff en School of Medicine, University of California at Los Angeles, 
10833 Le Conte Avenue, Los Angeles, CA 90095-1752, USA.
Published: 20 December 2013
References
1. Kim YJ, Kim EH, Hahm KB: Oxidative stress in infl ammation-based 
gastrointestinal tract diseases: challenges and opportunities. 
J Gastroenterol Hepatol 2012, 27:1004-1010.
2. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C: Chronic 
infl ammation and oxidative stress in human carcinogenesis. Int J Cancer 
2007, 121:2381-2386.
3. Feagins LA, Zhang HY, Zhang X, Hormi-Carver K, Thomas T, Terada LS, 
Spechler SJ, Souza RF: Mechanisms of oxidant production in esophageal 
squamous cell and Barrett’s cell lines. Am J Physiol Gastrointest Liver Physiol 
2008, 294:G411-G417.
4. Kong J, Stairs DB, Lynch JP: Modeling Barrett’s oesophagus. Biochem Soc 
Trans 2011, 38:321-326.
5. Spechler SJ, Fitzgerald RC, Prasad GA, Wang KK: History, molecular 
mechanisms, and endoscopic treatment of Barrett’s esophagus. 
Gastroenterology 2010, 138:854-869.
6. Sharma P: Clinical practice. Barrett’s esophagus. N Engl J Med 2009, 
361:2548-2556.
7. Espana EM, Shah S, Santhiago MR, Singh AD: Graft versus host disease: 
clinical evaluation, diagnosis and management. Graefes Arch Clin Exp 
Ophthalmol 2013, 251:1257-1266.
8. Scharl M, Rogler G: Infl ammatory bowel disease: dysfunction of 
autophagy? Dig Dis 2012, 30(Suppl 3):12-19.
9. Yuen E, Romney M, Toner RW, Cobb NM, Katz PO, Spodik M, Goldfarb NI: 
Prevalence, knowledge and care patterns for gastro-oesophageal refl ux 
disease in United States minority populations. Aliment Pharmacol Ther 
2010, 32:645-654.
10. Quante M, Abrams JA, Lee Y, Wang TC: Barrett esophagus: what a mouse 
model can teach us about human disease. Cell Cycle 2012, 11:4328-4338.
11. Washington K, Jagasia M: Pathology of graft-versus-host disease in the 
gastrointestinal tract. Hum Pathol 2009, 40:909-917.
12. Loftus Jr EV: Epidemiology and risk factors for colorectal dysplasia and 
cancer in ulcerative colitis. Gastroenterol Clin North Am 2006, 35:517-531.
13. Fein M, Peters JH, Chandrasoma P, Ireland AP, Oberg S, Ritter MP, Bremner CG, 
Hagen JA, DeMeester TR: Duodenoesophageal refl ux induces esophageal 
adenocarcinoma without exogenous carcinogen. J Gastrointest Surg 1998, 
2:260-268.
14. Garman KS, Orlando RC, Chen X: Review: Experimental models for Barrett’s 
esophagus and esophageal adenocarcinoma. Am J Physiol Gastrointest Liver 
Physiol 2012, 302:G1231-G1243.
15. Fitzgerald RC, Onwuegbusi BA, Bajaj-Elliott M, Saeed IT, Burnham WR, 
Farthing MJ: Diversity in the oesophageal phenotypic response to gastro-
oesophageal refl ux: immunological determinants. Gut 2002, 50:451-459.
16. Saleh M, Elson CO: Experimental infl ammatory bowel disease: insights into 
the host–microbiota dialog. Immunity 2011, 34:293-302.
17. O’Hagan HM, Wang W, Sen S, Destefano Shields C, Lee SS, Zhang YW, 
Clements EG, Cai Y, Van Neste L, Easwaran H, Casero RA, Sears CL, Baylin SB: 
Oxidative damage targets complexes containing DNA methyltransferases, 
SIRT1, and polycomb members to promoter CpG islands. Cancer Cell 2011, 
20:606-619.
18. Suzuki N, Yasui M, Geacintov NE, Shafi rovich V, Shibutani S: Miscoding events 
during DNA synthesis past the nitration-damaged base 8-nitroguanine. 
Biochemistry 2005, 44:9238-9245.
19. Agarwal A, Polineni R, Hussein Z, Vigoda I, Bhagat TD, Bhattacharyya S, Maitra 
A, Verma A: Role of epigenetic alterations in the pathogenesis of Barrett’s 
esophagus and esophageal adenocarcinoma. Int J Clin Exp Pathol 2012, 
5:382-396.
20. Kalabis J, Wong GS, Vega ME, Natsuizaka M, Robertson ES, Herlyn M, 
Nakagawa H, Rustgi AK: Isolation and characterization of mouse and 
human esophageal epithelial cells in 3D organotypic culture. Nat Protoc 
2012, 7:235-246.
21. Wang DH, Clemons NJ, Miyashita T, Dupuy AJ, Zhang W, Szczepny A, 
Corcoran-Schwartz IM, Wilburn DL, Montgomery EA, Wang JS, Jenkins NA, 
Copeland NA, Harmon JW, Phillips WA, Watkins DN: Aberrant epithelial–
mesenchymal hedgehog signaling characterizes Barrett’s metaplasia. 
Gastroenterology 2010, 138:1810-1822.
22. Clement G, Braunschweig R, Pasquier N, Bosman FT, Benhattar J: Alterations 
of the wnt signaling pathway during the neoplastic progression of 
Barrett’s esophagus. Oncogene 2006, 25:3084-3092.
23. Sato T, Stange DE, Ferrante M, Vries RG, Van Es JH, Van den Brink S, Van Houdt 
WJ, Pronk A, Van Gorp J, Siersema PD, Clevers H: Long-term expansion of 
epithelial organoids from human colon, adenoma, adenocarcinoma, and 
Barrett’s epithelium. Gastroenterology 2011, 141:1762-1772.
24. Buttar NS, Wang KK, Anderson MA, Dierkhising RA, Pacifi co RJ, Krishnadath 
KK, Lutzke LS: The eff ect of selective cyclooxygenase-2 inhibition in 
Barrett’s esophagus epithelium: an in vitro study. J Natl Cancer Inst 2002, 
94:422-429.
25. Kong J, Crissey MA, Stairs DB, Sepulveda AR, Lynch JP: Cox2 and 
Hartman et al. Stem Cell Research & Therapy 2013, 4(Suppl 1):S5 
http://stemcellres.com/content/4/S1/S5
Page 5 of 6
β-catenin/T-cell factor signaling intestinalize human esophageal 
keratinocytes when cultured under organotypic conditions. Neoplasia 
2011, 13:792-805.
26. Jung P, Sato T, Merlos-Suarez A, Barriga FM, Iglesias M, Rossell D, Auer H, 
Gallardo M, Blasco MA, Sancho E, Clevers H, Batlle E: Isolation and in vitro 
expansion of human colonic stem cells. Nat Med 2011, 17:1225-1227.
27. Lahar N, Lei NY, Wang J, Jabaji Z, Tung SC, Joshi V, Lewis M, Stelzner M, Martin 
MG, Dunn JC: Intestinal subepithelial myofi broblasts support in vitro and 
in vivo growth of human small intestinal epithelium. PLoS One 2011, 
6:e26898.
28. Spence JR, Mayhew CN, Rankin SA, Kuhar MF, Vallance JE, Tolle K, Hoskins EE, 
Kalinichenko VV, Wells SI, Zorn AM, Shroyer NF, Wells JM: Directed 
diff erentiation of human pluripotent stem cells into intestinal tissue in 
vitro. Nature 2011, 470:105-109.
29. Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, van Es 
JH, Abo A, Kujala P, Peters PJ, Clevers H: Single Lgr5 stem cells build crypt–
villus structures in vitro without a mesenchymal niche. Nature 2009, 
459:262-265.
30. Stelzner M, Helmrath M, Dunn JC, Henning SJ, Houchen CW, Kuo C, Lynch J, 
Li L, Magness ST, Martin MG, Wong MH, Yu J: NIH Intestinal Stem Cell 
Consortium. A nomenclature for intestinal in vitro cultures. Am J Physiol 
Gastrointest Liver Physiol 2012, 302:G1359-G1363.
doi:10.1186/scrt366
Cite this article as: Hartman KG, et al.: Modeling infl ammation and oxidative 
stress in gastrointestinal disease development using novel organotypic 
culture systems. Stem Cell Research & Therapy 2013, 4(Suppl 1):S5.
Hartman et al. Stem Cell Research & Therapy 2013, 4(Suppl 1):S5 
http://stemcellres.com/content/4/S1/S5
Page 6 of 6
